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Cancer is the second leading cause of death in the United States with colorectal cancer 
(CRC) being the third most common type. Available treatments include a combination of surgery 
and chemotherapy but have debilitating side effects. These also have limited effectiveness in 
some cases, creating the need for additional treatment options, or supplementary treatments to 
increase their effectiveness. This is leading scientists to consider the microbiome to fix this 
shortcoming. Current research is focusing on the microbiome and its interactions with certain 
diseases, which could lead to pro- or prebiotic therapies. This work aims to establish specific 
bacterial species can inhibit tumor cell growth and function. Conditioned media with a bacterial 
supernatant was added to cancerous and non-cancerous cells and their effect on the cell growth, 
proliferation, and invasiveness was assessed. It was determined that Lactobacillus intestinalis, 
Bacteroides uniformis, Bacteroides thetaiotaomicron, and Prevotella copri all show potential in 
reducing cancer cell growth. This work demonstrates the potential to significantly enhance 
current immunotherapies and/or replace chemotherapies as well as aid in the understanding of 
the role of the microbiome in cancer.  
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Cancer remains one of the more complex human diseases, affecting a large percentage of 
the world population. It is also one of the most deadly, being the 2nd leading cause of death in the 
United States 1. Current treatment include a combination of surgery and chemotherapy. Although 
chemotherapy has shown some success in treating colorectal cancer (CRC) it comes with serious 
side effects that can reduce the quality of life of the patient. One study has reported side effect  
from cancer patients, showing a range of symptoms including chest pains, constipation, diarrhea, 
fatigue, general pain, rash, and vomiting among the most common 2. The problem with these 
therapies is not only the debilitating side effects they induce, but also that they are not always 
effective. A new rise of immunotherapies are attempting to solve both of these problems 
including various program cell death protein 1 (PD-1) blocking strategies to increase the host 
immune response to CRC tumors3–5. This screening study attempts to supplement these 
immunotherapies through the utilization of the microbiome by identifying potential microbes 
that inhibit cancer cell division and viability. 
 As more research is being focused on the microbiome and its interactions with various 
diseases, it is a clear next step to look for its interactions with cancer cells and tumors that much 
microbiome research is now focusing on. Studies have found differences in bacteria when 
comparing CRC tumors and non-cancerous surrounding tissue6–8. Some of the primary bacteria 
found on healthy tissue include Prevotella, Bacteroides, Feacalibacterium prausnitzii, and 
Bifidobacterium7,8. These bacteria differ from those found on the CRC tumors through their 
production of butyrate.6. Butyrate is an essential energy source for colon cells9, induce p21 
dependent cell cycle arrest and apoptosis in cancer cells6, and have anti-inflammatory effects10. 
Additionally, one study has used Lactobacillus (another butyrate producer) to create conditioned 
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media and showed inhibition of cancer cell progression in mice11. This screening study will 
assess the ability of various common human gut microbes to inhibit cancer growth in culture. 
Colorectal Cancer 
Being one of the most prevalent cancer types in the United States, being estimated to 
afflict ~150,000 people12 and posing a large problem globally, there is much known about CRC. 
Both genetic and environmental links have been uncovered. Colorectal cancer results from the 
accumulation of both genetic and epigenetic changes within colonic epithelial cells that leads to a 
transformation into a cancerous cell13. Many factors can influence the formation of these 
cancerous cells, including dysregulation of several key signaling pathways including Wnt/β-
catenin involved in intestinal epithelial regeneration14, TGF-β/SMAD involved in cell 
proliferation, differentiation, migration and apoptosis13,15, Notch signaling involved in intestinal 
epithelial proliferation16, and Hedgehog signaling involved in cell proliferation17. These and 
others have been identified as improperly functioning due to one or several parts of the pathway 
containing a detrimental mutation creating a hyper- or hypoactive pathway leading to cancerous 
formation. Dysregulation in these pathways and others related to CRC can also create loss of 
function of pathways involved in cellular apoptosis and general tumor suppression.  
Acquiring the types of mutations that result in cancer formation has been related to many 
factors identified as high-risk environmental factors. Risk factors can include a range of habits 
from dietary to lifestyle. Some of the most notable include smoking18,19, alcohol consumption19, 
excess body weight20, and poor diet (high consumption of processed meat, low fruit/vegetable 
consumption, and low dietary fiber consumption)21. All these factors have been linked to 
increased risk of developing various types of cancer, including colorectal cancer though the 
mechanism through which these can increase risk is unknown to some extent.  
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To study the mechanisms of cancer progression and treatment, various model systems are 
used with associated benefits and pitfalls for each. One of the least invasive methods to study 
CRC are statistical analyses to identify strong correlations between cancer risks and genetic, 
environmental, and lifestyle habits12. These type of bioinformatic assessments give important 
insight and direction into future studies to further investigate these correlations with in vitro and 
in vivo methods. In vivo methods can be done in mice, one of the most common model 
organisms. Mouse models are continually used due to their many homologous genes and diseases 
that can model those present in humans. In the case of CRC, mouse models have been used to 
study the role of oncogenes like K-ras through the creation of knockout and knockdown 
models22. In vitro models can also be used for many studies using cell culture methods to look 
in-depth at the cellular responses. CRC cells in culture have been used to research many 
colorectal cancer therapies and mechanisms.  
The SW480 cell line is a Human Duke’s type B (stage II) colorectal adenocarcinoma 
which has been used to study the interaction with Ferulago species of bacteria originating from 
Turkey23,24. This line has also been the model for research into various potential anticancer 
compounds such as quercetin25 and resveratrol26. SW480 cells have also been used to study 
interactions of receptors such as the estrogen receptor β and its role in tumor repression27. The 
LoVo cell line is a Human Duke’s type C (stage III) colorectal adenocarcinoma cell line that has 
also been utilized as an in vitro model to develop a 3-D spheroid model for colorectal cancer28 to 
more closely mimic the tumor environment in vitro. LoVo cells have also been used to study 
mutations associated with CRC like in the endoprotease furin29, as well as responses to potential 
anticancer compounds like baicalein and luteolin30. In this study, cell culture was also used as the 
model of choice to understand at a fundamental level, the effects of the microbiome 
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macromolecular microbial components and metabolites on CRC. This fundamental look into 
interactions at the cellular level will expand on the findings of in vivo and computational studies 
to pave the way to potential anticancer strategies through specific microbial interactions. 
Colorectal Cancer Diagnosis and Treatments 
Colorectal cancer, having a high incidence rate, requires early diagnosis and effective 
treatments for optimal patient outcomes. Diagnosis can occur with a variety of methods 
including the most common and widely accepted, colonoscopies. Colonoscopies can also be 
useful in the collection of biopsy samples and in reducing the incidence of CRC mortality 
through colonoscopic polypectomies31,32. This procedure allows for both rapid diagnosis as well 
as the potential for CRC prevention. Additional diagnostic tools include capsule endoscopy and 
CT colonography in addition to less invasive methods such as the detection of CRC biomarkers 
present in the blood, stool, and urine of patients33.  
Treatment options for CRC once identified are limited and are often the focus of research 
in this field to increase patient outcomes after diagnosis. The current standards of treatment 
include surgical intervention to remove all traces of the tumor and metastases as well as 
chemotherapy as either a supplemental treatment  post-surgery to increase effectiveness, or as 
first-line treatments prior to surgical intervention34–36. In many cases these current treatments are 
not enough or in the case of chemotherapy, cause severe side-effects for the patient. For these 
reasons, continued research efforts are devoted to finding alternative treatments that are more 
effective and cause less severe side-effects. Immunotherapies are becoming one such treatment 
option that have been showing great promise in their long-term effectiveness against certain 
cancers. In CRC specifically, there has been some promise shown with anti-PD-1 therapies that 
had limited success with re-induction therapy to invoke the host immune response4. Problems 
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occur in tumors with high levels of mutations that lead to overcoming even anti-PD-1 therapies5. 
In many cases, the metastatic migration of cancer cells causes the main issue for all current 
therapy types. These treatment options are promising even with the known drawbacks, but this 
highlights the important need for more treatment options for individuals diagnosed with CRC.  
Colorectal Cancer and the Microbiome 
 In the direction of combatting colorectal cancer, the microbiome has received attention, 
especially in recent years. Intense research into this area in recent years has uncovered numerous 
causal links between microbial composition and function, unveiling the etiology of many 
diseases, disorders and conditions and have further shown the molecular mechanisms behind 
these links. The microbiome has been demonstrated to work through various mechanisms which 
include modulation of the immune system through signaling to directly induce T-cell 
differentiation in the gut37, as well as through their normal metabolic pathways that result in 
metabolite release into the body that can also play a role in T-cell development38. Manipulating 
this interplay between the microbiome and the immune system is the primary avenue to both 
prevent and combat human diseases. Fasting is one method that is showing promise through the 
increase in bacterial diversity in the gut as well as the specific outgrowth of bacteria that show 
therapeutic effects in diseases like multiple sclerosis (MS)39. Other methods of altering the 
microbiome are through pro- and pre- biotic treatment to directly introduce bacteria of interest. 
This can be an effective approach to supplement therapeutic bacteria into the human gut.  
 As it relates to CRC, the microbiome has been studied with the mindset of determining 
correlations with the various microbes and outcomes of the disease with the intention of finding 
bacteria that may have anticancer effects. Summaries of findings show an overall decrease in 
diversity in the microbiome of CRC patients alongside an increase in specific bacterial 
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abundance such as some species of Bacteroides and Prevotella that have been linked to CRC40. 
These can outcompete known therapeutic bacteria for the growth, which typically includes short-
chain fatty acid (SCFA) producers. There are also studies that suggest dysbiosis of the gut 
microbiome is the main cause of CRC through inflammation that induces epithelial cell 
transformation into cancerous cells41. In the same light, diet has a large impact on both the 
microbiome and CRC as poor diet (high consumption of processed meat, low fruit/vegetable 
consumption, and low dietary fiber consumption) is a known risk factor for CRC21,42 that may 
alter the gut microbiome. Diet has been shown to impact the microbiome and predict bacterial 
enterotypes. One study showed the link between two highly common enterotypes and diet where 
those with diets high in protein and animal fats predominantly had Bacteroides present in their 
microbiome, while those consuming more carbohydrates resulted in higher Prevotella 
abundance43. Therefore, it is reasonable to link poor diet and CRC via a microbiome mediation. 
Regardless of the role that the microbiome plays, though it is suggested to be a pivotal role in 
cancer progression, microbiome scientists tend to agree that the impact of the microbiome is 
substantial and requires investigation. This study strives to add to this pool of knowledge and aid 




MATERIALS AND METHODS 
Cell Culture 
SW480 cells and LoVo cells, two human CRC cell lines, were utilized in this study 
donated from Dr. Daniel W. Rosenberg’s lab (UConn Health Center). Each of these cell lines is a 
type of colorectal cancer with previous research behind them and are aggressive forms of CRC. 
Cells were cultured in DMEM/F12 media (Corning™ DMEM/Ham's F-12 50/50 Mix, Powder 
MT90091PB) supplemented with 10% Fetal Bovine Serum (Gemini, Cat# 100-106) and 1% 
penicillin streptomycin glutamine (ThermoFisher Scientific, Waltham, MA, USA, Cat# 
10378016). Incubation was done at 37℃ in 5% carbon dioxide (CO2) in a humidified incubator. 
Bacterial Species 
Bacterial species used included six different bacteria already isolated and growing in Dr. 
Yanjiao Zhou’s lab (UConn Health Center). Three Lactobacillus species including L. reuteri 
(ATCC 23272), L. johnsanii (ATCC 33200), and L. intestinalis (ATCC 49335) were all used and 
grown in both MRS media (MRS Broth modified, Vegitone, Millipore Sigma, 38944-F) 
supplemented with tween 80 (Millipore Sigma P4780) and TSB (Tryptic Soy Broth, Millipore 
Sigma, T8907). TSB was used prior to conditioned media creation as MRS broth is an acidic 
selection media for Lactobacillus species. Prevotella copri (DSM 18205) was isolated and 
grown in BHI media (Thermo Scientific™ Brain Heart Infusion Broth (Dehydrated), CM1135B) 
supplemented with 10mL/L Hemin Solution (Millipore Sigma H9039) and 0.2mL/L Vitamin K1 
Solution (Millipore Sigma, 95271). Two Bacteroides species, thetaiotaomicron (ATCC 29148) 
and uniformis (ATCC 8492), were also grown in BHIS media. BHIS media was created using 
the ATCC formulation 1293 Brain heart infusion-supplemented (BHIS), which uses the BHI 
base supplemented with Hemin and Vitamin K1. All bacteria are anaerobic and were therefore 
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grown in a Bactronez anaerobic chamber with an anaerobic gas mixture of 5% carbon dioxide, 
5% hydrogen, and 90% nitrogen from AirGas.  
Conditioned Media 
Conditioned media was made for each of the bacteria less than one week prior to use. 
Bacteria were grown in their appropriate broth media at a final volume of 50mL. Lactobacillus 
species were grown for 48 hours prior to isolation of supernatant, while the P. copri and 
Bacteroides species required only 24 hours before they were ready to process. After the growth 
period, the tubes were sealed and spun for 5 minutes at 1,000xg before being filtered through a 
0.2um polyether sulfone (PES) filter. The cell-free bacterial supernatant preparation was adapted 
from previous studies44,45. After preparation of cell-free bacterial supernatant was complete, 
three conditioned media formulations were made containing 50%, 25%, and 10% bacterial 
supernatant in complete F12 cell media which was stored at 4℃ until used within a week of 
creation. Sterile media was used to create the same three concentrations of control conditioned 
media to exclude effects of the bacterial media on the CRC cells. 
Cell Proliferation Assessment 
Effects of the conditioned media on each CRC cell line was observed via confluence and 
morphological changes. Baselines of each cells’ growth was noted to establish normal growth 
confluence changes and morphology. Additionally, the control conditioned media was used to 
exclude effects of the bacterial media on the CRC cells. Cell counts and viability determinations 
were preformed after confirmation of effects using the Countess™ II Automated Cell Counter to 
avoid bias during cell counting and maintain consistency both before and after the addition of 
conditioned media. Trypan blue was used for viability determination. Graphs were created using 




Growth Changes with Lactobacillus Conditioned Media 
As both a confirmatory test for the model system used, and an experimental test, several 
Lactobacillus species were used to create conditioned media. Both SW480 and LoVo cells were 
grown with the varying concentrations (50%, 25%, and 10% bacterial supernatant) alongside 
TSB controls to exclude bacterial media related effects on growth. Only one well of a six-well 
plate was used for each of the conditions. L. reuteri and L. johnsanii species showed no visible 
effect on the growth or morphology of either cell lines after five days.  
L. intestinalis was also tested and showed slight growth reduction in SW480 cells. As 
shown in Figure 1, a comparison between the TSB controls (Figure 1A, C, and E) and the L. 
intestinalis (Figure 1B, D, and F) shows slight confluence reduction between 3-5% in most cases. 
Each concentration shows two images of the same well in different locations to ensure 
uniformity throughout the well and avoid misleading results due to varying cell confluence 
across the well. Comparing Figure 1E and 1F, 10% TSB and 10% L. intestinalis respectively, 
there is a more noticeable difference of 10-15% confluence change. In addition to the confluence 
changes, cell morphology is noticeably more spherical indicating potential attachment issues in 
the cells cultured with L. intestinalis conditioned media. This morphology is present in the TSB 
controls, but to a lesser extent indicating either growth delay and delay in attachment, or 
prevention of growth and/or attachment.  
Similar results are indicated with the LoVo cell line, but current results are unclear. 
Grown in parallel with the SW480 cells, the LoVo cells were plated in varying concentrations of 
the L. intestinalis conditioned media and TSB control conditioned media to visualize changes in 
growth and/or morphology. In Figure 2A, C, and E, cells were grown in 50%, 25%, and 10% 
11 
 
TSB respectively as points of comparison for growth in the same concentrations of bacterial 
conditioned media. Figures 2B, D, and F show growth in 50%, 25%, and 10% of L. intestinalis 
conditioned media. When comparing the growth conditions, changes are subtle and may be 
related to the bacterial supernatant or may be a result of outside factors. The 50% wells show 
some confluence reduction of approximately 5%, however, no other concentrations have 
noticeable reduction in confluence. Additionally, no clear morphological changes can be seen in 
any concentration of bacterial supernatant.  
SW480 Cell Response to Bacterial Conditioned Media 
In addition to Lactobacillus species, the SW480 cell line was tested with three other 
bacteria including Bacteroides uniformis, B. thetaiotaomicron, and Prevotella copri. Noticeable 
differences were seen with all three bacterial conditioned medias. In terms of morphological 
changes, the 10% P. copri supernatant well showed a clear change from individually attached 
cells to clustered cell groups (Figure 3). The morphology change is clear starting at day three 
post-plating (Figure 3A and B) and continued to move towards tumor-like formations at day five 
(Figure 3C and D). This was the only morphological change seen specifically in the SW480 cells 
with 10% P. copri supernatant in the growth media. 
Confluence changes were tracked for three timepoints at day two, three, and five post-
plating (Figure 4). Increases in confluence can be seen with all control BHIS groups, but most 
notably with 10% BHIS. This may indicate slight inhibition of growth due to the bacterial media 
supplementation with the standard F12 growth media. B. uniformis conditioned media shows 
reduced confluence overtime in the 50% and 25%, while the 10% group shows an increase 
comparable to the 10% BHIS control group. Potential growth inhibition can be seen at the higher 
concentrations of B. uniformis conditioned media. Observing the B. thetaiotaomicron and P. 
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copri conditioned media confluence changes, similar results to each other are found. Confluence 
appears to increase slightly, but plateau at about 50% confluence. In all cases excluding the 10% 
B. thetaiotaomicron group, the confluence percentages are lower than all BHIS control groups 
indicating some effect for almost all groups. This is corroborated with live cell counts showing 
similar changes comparing the cell counts of the control groups with the B. uniformis, B. 
thetaiotaomicron, and P. copri groups (Figure 5). Viability did not appear to correlate with any 
bacterial conditioned media (Table 1). 
LoVo Cell Response to Bacterial Conditioned Media 
 Similarly, to the SW480 cells, LoVo cells were tested under the same conditions in 
parallel. Unlike the SW480 cells however, the LoVo cells showed unclear and inconsistent 
results with conditioned media from B. uniformis, B. thetaiotaomicron, and P. copri. No 
morphological changes were visible, and cells had an overall low density in all conditions 
including control plates.  
 Looking at confluence changes, effects of the conditioned media was unclear. In all 
control BHIS groups, confluence had a net loss indicating there may be an effect of the BHIS 
media itself on the LoVo cell growth, or outside factors contributed. The cell counts substantiate 
the role of outside factors on the cell growth showing an increase in live cells only in the 25% 
BHIS control group, yet a loss in live cells in all other groups. Viability was on average, lower 
than SW480 cells in the same conditions, but does not show any relationships with either the 





The goal of this screening study was to determine if bacteria commonly found in the 
human gut had an anticancer effect on colorectal cancer cells in culture. Determination of 
bacterial species that may exhibit therapeutic effects in relation to CRC can direct future studies. 
Using isolated bacterial supernatants to create conditioned media, we found potential therapeutic 
candidates that likely secrete a metabolite able to reduce CRC growth in culture. Similar studies 
have found butyrate and other SCFAs to invoke therapeutic responses such as p21 mediated or 
ferrichrome induced apoptosis6,11. Similar mechanisms may be used by the identified anticancer 
bacteria in this study including Lactobacillus intestinalis, Bacteroides uniformis, Bacteroides 
thetaiotaomicron, and Prevotella copri. 
Three Lactobacillus species were tested, being reuteri, johnsanii, and intestinalis. Despite 
Lactobacillus being a family of bacteria that is associated with therapeutic responses to 
cancer11,44, only one strain, intestinalis  was identified as showing a slight therapeutic effect. This 
was observed with 10-15% confluence reduction in the SW480 cell line, but only a 3-5% 
reduction with the LoVo cell line (Figure 1 and 2). These results were seen with the 10% and 
50% L. intestinalis media with SW480 cells and LoVo cells, respectively. This indicates L. 
intestinalis may share the positive effect with previously studied Lactobacillus species. From 
current results it is not clear whether L. reuteri or L. johnsanii have similar effects, but more 
evidence may support this. 
The remaining three bacteria tested, B. uniformis, B. thetaiotaomicron, and P. copri, all 
showed stronger results than the Lactobacillus species tested. In the SW480 cell line, several 
noteworthy observations were made when cultured with the P. copri conditioned media. A clear 
morphological change can be seen in Figure 3B and D, where the 10% P. copri conditioned 
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media likely caused the SW480 cells to grow into tumor-like clusters. This is atypical of this cell 
line as shown in Figures 3A and C where individual cells are easily observed with an epithelial-
like morphology. This morphological change did not, however, occur in any other concentrations 
of P. copri conditioned media or any other growth condition indicating this may be an isolated 
event, but still warrants further investigation. Additionally, the LoVo cell line did not exhibit any 
clear morphological changes with any of the conditioned medias. 
 Alongside morphology, cell confluence changes were monitored during cell culturing 
with conditioned medias, and cell counts were determined after five days in culture. Conclusions 
can be drawn from the results of the SW480 cell line experiments, however, the results of the 
LoVo cell line are unclear. Cell counts from the control groups are unclear and therefore 
comparisons are unable to be made. This may be due to significant effects of the BHIS media on 
the LoVo cell growth, however, additional experiments must be run to confirm this. In the 
SW480 cell line, a potential reduction in growth may have been observed due to the bacterial 
control media group, as the 10% BHIS control group showed the largest confluence increase 
overall in these cells (Figure 4). Analyzing the cell counts, the initial plated cell count was 1x106 
cells, indicated by the grey bars in Figure 5. As shown by this figure, all conditioned medias 
appear to have reduced growth in the SW480 cells when compared to the BHIS controls. There 
also appears to be a dose-dependent effect moving from 10% conditioned media to 50% that is 
observed to a lesser extent in the BHIS control groups. This could be a result of higher 
concentrations of the key therapeutic metabolite that each bacterium is producing, leading to 
cellular death in the CRC cell line. Key therapeutics could range from SCFAs like butyrate that 
has been identified as therapeutic6,9,10 or other potential unidentified compounds that may have 
anti-inflammatory affects, or otherwise affect the CRC cells more like butyrate through p21 
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mediated apoptosis. This could also be attributed to high concentrations of lipopolysaccharide 
(LPS) which is a known component of gram-negative bacterial outer membranes. Other studies 
investigating the microbiome have identified the Bacteroides and Prevotella families of bacteria 
to be therapeutic through both meta-analysis40 and through correlations with lessened MS disease 
severity46. One unpublished work from Dr. Zhou’s lab implicates increased red meat intake with 
reduced B. thetaiotaomicron and increased severity of MS, also showing B. thetaiotaomicron as 
a potential therapeutic bacteria47. Evidence of other Bacteroides species exhibiting pro-
inflammatory responses, however, such as B. fragilis that have also been linked to CRC41,48. 
Additional research must be done in relation to CRC to show the interactions in this type of 
cancer as either therapeutic or antagonistic overall.  
 Moreover, the results obtained through this study pave the way for future studies to 
further the knowledgebase of the microbiome and CRC. An avenue for continuing includes 
exploring the interactions between the microbiome and T-cells specifically as there is already 
evidence of the microbiome influencing T-cell differentiation in the gut37,38. Utilizing in vivo 
mouse studies to colonize with each individual bacterium followed by subsequent isolation and 
characterization of the T-cells could discern alternative mechanisms through which the tested 
bacteria can play a therapeutic role in the context of CRC. In the same light, further in vitro 
testing can be done on both T-cells in culture and non-cancerous colorectal cells. Observing and 
characterizing T-cells in culture can give insight into the direct interactions between the bacterial 
metabolites and immune cell differentiation. Observations of non-cancerous cells would show 
any potential adverse effects on surrounding tissue if bacterial therapies were to move forward as 
a potential therapeutic for CRC patients.  
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 In summary, the results obtained from this screening study are limited, but justify the 
further exploration of how the microbiome interacts with colorectal cancer. The bacteria that 
show noticeable differences in cell morphology and cell numbers, after conditioned media 
treatment, especially warrant further investigation to confirm the results of this study and 
determine potential mechanisms for their inhibition of tumor cell growth. Many potential 
treatments for CRC and other human cancers are being explored, and the microbiome is yet 





Figure 1: Images depicting the growth of SW480 cells in TSB control and L. intestinalis 
conditioned media three days after plating. A, C, and E show the TSB control conditioned media 
at 50%, 25%, and 10% TSB, respectively. B, D, and F show the L. intestinalis conditioned media 




Figure 2: LoVo cell growth three days after passaging into conditioned media. A, C, and E show 
TSB control conditioned media at 50%, 25%, and 10% concentrations, respectively. B, D, and F 





Figure 3: Morphology of SW480 cells in BHIS control and P. copri conditioned media. (A) 
BHIS control conditioned media at 10% BHIS three days after plating. (B) 10% P. copri 
conditioned media three days after plating. (C) 10% BHIS control conditioned media five days 





Figure 4: Descriptive graph of SW480 cell confluence changes over the course of five 
days being cultured in conditioned media. Cells were grown in a six-well plate and seeded at 




Figure 5: Descriptive graph of cell counts of live SW480 cells plated in varying conditioned 
media including BHIS (SW480 control), B. uniformis supernatant, B. thetaiotaomicron 
supernatant, and P. copri supernatant alongside the initial plated cell count of 1x106 cells. Data 





Figure 6: Descriptive graph of LoVo cell confluence changes over the course of five 
days being cultured in conditioned media. Cells were grown in a six-well plate and seeded at 






Figure 7: Descriptive graph of Live cell counts of LoVo cells plated in varying conditioned 
media including BHIS (LoVo control), B. uniformis supernatant, B. thetaiotaomicron 
supernatant, and P. copri supernatant alongside the initial plated cell count of 1x106 cells. Data 






SW480 Cells LoVo Cells 
Condition Live Count Viability Live Count Viability 
BHIS 10%  3.33E+06 98.00% 2.70E+05 98.00% 
BHIS 25%  4.10E+06 100.00% 1.29E+06 80.00% 
BHIS 50% 2.64E+06 94.00% 5.00E+05 91.00% 
B. uniformis 10%  1.45E+06 100.00% 4.46E+05 92.00% 
B. uniformis 25%  1.29E+05 55.00% 7.62E+04 92.00% 
B. uniformis 50% 5.28E+04 100.00% 3.52E+04 50.00% 
B. thetaiotaomicron 10%  2.89E+06 100.00% 2.76E+05 96.00% 
B. thetaiotaomicron 25%  4.34E+05 86.00% 4.16E+05 93.00% 
B. thetaiotaomicron 50% 6.45E+04 82.00% 2.17E+05 92.00% 
P. copri 10%  1.17E+06 100.00% 7.21E+05 100.00% 
P. copri 25%  8.45E+05 89.00% 1.52E+05 88.00% 
P. copri 50% 5.86E+03 100.00% 1.17E+04 50.00% 
 
Table 1: Live cell counts, and viability percentages determined via trypan blue staining for each 
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